Improved survival with postoperative uracil-tegafur in stage 1 adenocarcinoma of the lung

While fluorouracil itself has no apparent effect on survival in non-small cell lung cancer, Japanese studies of uracil-tegafur have reported a mortality benefit when used as an adjuvant therapy.

Saved in:
Bibliographic Details
Published inThorax Vol. 59; no. 7; p. 573
Main Author Lawson, M H
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group LTD 01.07.2004
BMJ Group
Subjects
Lung Alert
Mortality
Patients
Online AccessGet full text

Cover

More Information
Summary:While fluorouracil itself has no apparent effect on survival in non-small cell lung cancer, Japanese studies of uracil-tegafur have reported a mortality benefit when used as an adjuvant therapy.
ISSN:0040-6376
1468-3296
DOI:10.1136/thx.2004.la0099